IRESSA (gefitinib, ZD1839) – AstraZeneca Oncology

Lung cancer treatment options

Only about 20% of cases of non-small cell lung cancer (NSCLC) are suitable for resection at presentation. Lung cancer treatment strategies are dependent on the tumour size, location and extent of the tumour invasion, and the general health of the patient.

Search

Patients & Carers

Site services